Efficacy and Safety of 4.5mg PEG-rhG-CSF Per Cycle in Preventing Neutropenia After Intensive Chemotherapy for Breast Cancer
This is a prospective, single-center, single-arm clinical study, to evaluate the clinical efficacy, safety and tolerance of patients with early breast cancer receiving ddEC adjuvant chemotherapy, accepting PEG-rhG-CSF as primary prevention of neutropenia.
Breast Cancer|Neutropenia
DRUG: PEG-rhG-CSF
RDI for each EC chemotherapy, Ratio of actual dose intensity to standard dose intensity, 60 days after the first chemotherapy|Chemotherapeutic dose adjustment due to neutropenia, percentage of dose decreasing due to neutropenia, 60 days after the first chemotherapy|overall completion rate of chemotherapy, calculate the overall chemo-completion rate among all patients, 60 days after the first chemotherapy
Incidence of febrile neutropenia, 60 days after the first chemotherapy|Incidence of Grade 3/4 ACN reduction, evaluate the incidence of Grade 3/4 absolute neutrophil count, 60 days after the first chemotherapy|Duration of Grade 3/4 ACN reduction, observe the duration of Grade 3/4 absolute neutrophil count, 60 days after the first chemotherapy
This is a prospective, single-center, single-arm clinical study, to evaluate the clinical efficacy, safety and tolerance of patients with early breast cancer receiving ddEC adjuvant chemotherapy, accepting PEG-rhG-CSF as primary prevention of neutropenia.